Agents Available Under CTEP Collaborative Agreements
Agents under a CTEP Cooperative Research and Development Agreement (CRADA) may be requested by the grantee organization in CTEP-supported clinical trials networks (ETCTN, NCTN, PEP-CTN, and PBTC) for use in clinical and non-clinical research.
If the agent you are looking for is not on this list please also check the NCI Formulary. Information about clinical requests for these agents is available on the Trial Development page.
Table of Available Agents
This table shows agents available under CTEP collaborative agreements, including basic information about each agent and the IDB Drug Monitor for each agent. Refer to any footnotes for potential restrictions.
You can also download an Excel spreadsheet of the agents with active agreements as of the update date. (Updated June 5th, 2025).
CAUTION: The table is updated about 4 times per year and may not include the most recent changes. You may contact the appropriate drug monitor to confirm availability of a specific agent. For any other questions, please email NCICTEPRequests@mail.nih.gov.
| Agent Name | Alternate Name | Pharmaceutical Collaborator | NSC Number | Drug Monitor | Mechanism of Action | Targets | Classes |
|---|---|---|---|---|---|---|---|
| Acalabrutinib | AstraZeneca | 806311 | Gore | Selectively inhibits Bruton’s tyrosine kinase (BTK) with minimal effects on TEC, EGFR, and ITK signaling. | Bruton’s tyrosine kinase (BTK) | Small Molecule | |
| Actimab-A | Actinium Pharmaceuticals, Inc. | 843488 | Pelosof | Antibody Radioconjugate comprising the alpha-particle emitting radionuclide actinium-225 (Ac225) conjugated to lintuzumab, a humanized anti-CD33 monoclonal antibody | CD33+ myeloid-derived suppressor cells (MDSCs) | Antibody Radioconjugate | |
| Amivantamab | JNJ-61186372 | Janssen Scientific Affairs, LLC | 842127 | Pickett | Inhibits EGFR and MET signaling | Extracellular domains of EGFR and MET | Bispecific Antibody |
| APG-1252 | Pelcitoclax | Ascentage | 831685 | Gore | Inhibits B-cell lymphoma 2 (Bcl-2) and B-cell lymphoma extra-large (Bcl-xL) | anti-apoptotic Bcl-2 family proteins, including Bcl-2, Bcl-xL, Bcl-w, and Mcl-1 | Small Molecule |
| ASTX727 2 | Fixed-Dose Combination of cedazuridine and decitabine | Taiho Oncology | 820631 | Pelosof | DNA methyltransferase (DNMT) inhibitor | DNA methyltransferase | Small Molecule |
| Atezolizumab | MPDL3280A | Genentech | 783608 | Chen | Targets PD-L1 expressed on tumor and infiltrating immune cells, preventing binding to PD-1 and B7.1 | programmed cell death ligand 1 (PD-L1) | Monoclonal Antibody |
| AZD5363 | Capivasertib | AstraZeneca | 782347 | Pelosof | Inhibits all AKT isoforms | AKT | Small Molecule |
| Balstilimab 5 | AGEN2034 | Agenus | 853950 | Pickett | Binds PD-1 to prevent the interaction between the receptor and its ligands. | PD-1 | Monoclonal Antibody |
| Belinostat | PXD 101 | Acrotech Biopharma | 726630 | Pelosof | Histone deacetylase inhibition | Histone deacetylase | Hydroxamic acid |
| Bevacizumab | rhuMAb VEGF | Genentech | 704865 | Pickett | Binds VEGF to prevent its binding to VEGFR; angiogenesis inhibition | VEGF | Monoclonal Antibody (Humanized) |
| Blinatumomab | AMG-103, MT-103 | Amgen | 765986 | Pickett | bispecific (BiTE specific) antibody targeting CD19 | CD19 | Monoclonal Antibody |
| Botensilimab | AGEN1181 | Agenus | 853990 | Pickett | Binds to CTLA-4 to inhibits the CTLA-4-mediated downregulation of T-cell activation. | CTLA-4 | Monoclonal Antibody |
| Brentuximab vedotin | SGN-35 | Seattle Genetics | 749710 | Pickett | An antibody drug conjugate targeting CD30 and using an MMAE payload | CD30 | Antibody-Drug Conjugate |
| CA-4948 | Interleukin-1 Receptor-Associated Kinase 4 (IRAK-4) Inhibitor | Curis, Inc. | 824184 | Pickett | Inhibits TLR and IL-1R signaling; Inhibits myddosome signaling; inhibits NFkB activity | IRAK4 and IRAK4-L | Small Molecule |
| Cabozantinib | XL-184 | Exelixis | 761968 | Gore | c-Met; VEGFR2 inhibition | c-Met; VEGFR2 | Small Molecule |
| CBX-12 | Alphalex-exatecan | Cybrexa 2, Inc | 828474 | Gore | Alphalex conjugate that contains a topoisomerase I inhibitor exatecan | Topoisomerases I | Peptide Drug Conjugate |
| CDX-1140 | Celldex | 841752 | Pickett | Agonist anti-CD40 monoclonal antibody that inhibits cancer cell proliferation or triggers apoptotic cell death | Human CD40 | Monoclonal antibody (mAb) | |
| Cediranib 1 | AZD2171 | AstraZeneca | 732208 | Pelosof | Angiogenesis inhibitor, VEGFR1, VEGFR2, VEGFR3, PDGFR alpha and beta, FGFR1 | VEGFRs, PDGFRs, FGFR1 | Small Molecule |
| Cemiplimab | REGN2810 | Regeneron | 788843 | Pickett | Inhibits programmed death receptor-1 | Programmed cell death 1 (PD-1) on the surface of immune cells | Monoclonal Antibody |
| Cirtuvivint | Biosplice Therapeutics, Inc | 835563 | Gore | Inhibits CDC-Like Kinases (CLK) and Dual-Specificity Tyrosine-Regulated Kinases (DYRK) | CLK/DYRK kinase | Small Molecule | |
| Dabrafenib mesylate 1 | GSK2118436B | Novartis | 763760 | Chen | BRAF inhibition of BRAFV600 mutations | BRAF | Small Molecule |
| Darolutamide | BAY-1841788 | Bayer | 815949 | Pelosof | A novel nonsteroidal androgen receptor (AR) antagonist | androgen receptor (AR) | Small Molecule |
| DAY101 | Tovorafenib | Day One Biopharmaceuticals, Inc. | 800798 | Gore | A selective Type II pan-RAF kinase inhibitor | pan-RAF kinase | Small Molecule |
| Dinutuximab | Ch14.18 | United Therapeutics | 764038 | Chen | Antibody against GD2 | GD2 | Monoclonal Antibody (chimeric) |
| DSP-5336 | Enzomenib | Sumitomo Pharma America, Inc. | 855950 | Gore | Menin inhibitor | Menin | Small Molecule |
| Durvalumab | MEDI4736 | AstraZeneca/Medimune | 778709 | Chen | Check point inhibitor. Antibody against programmed cell death ligand 1 (PD-L1) | PD-L1 | Monoclonal Antibody |
| Fianlimab | Regeneron | 847987 | Pickett | Inhibits immune checkpoint receptor LAG-3 | LAG-3 on T cells | Monoclonal Antibody | |
| Giredestrant | GDC-9545 | Genentech | 840836 | Pickett | Selective estrogen receptor degrader (SERD) | Competitively binds to the ligand binding-domain (LBD) of both wild-type and mutant estrogen receptor (ER) | Small Molecule |
| Glofitamab | RO7082859 | Genetech | 845088 | Ko | promotes T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells | bivalency for CD20 on B cells and monovalency for CD3 on T cells. | Bispecific antibody |
| Iberdomide | Bristol Myers Squibb | 833899 | Pelosof | Immunomodulatory therapeutic | Induces degradation of transcription factors Aiolos and Ikaros | Small Molecule | |
| idUrd Prodrug | IPdR | NCI | 726188 | Pelosof | Prodrug of iododeoxyuridine | DNA polymerase | Small Molecule |
| IMC-F106C | Immunocore | 853198 | Ko | An immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC) for the treatment of cancers positive for the tumor-associated antigen PRAME. | TCR bispecific protein targeting CD3 and PRAME | Monoclonal Antibody | |
| Inavolisib | GDC-0077 | Genentech | 843575 | Gore | Selectively inhibits the Class I PI3Kα isoform (p110α), with minimal inhibition of the Class I PI3K β, γ, and δ isoforms | Class I PI3Kα isoform (p110α) | Small Molecule |
| Interleukin-12 | IL-12 | NCI | 672423 | Chen | Made mainly by dendritic cells and macrophages. Causes other immune cells to make cytokines and increases the growth of T lymphocytes. It may also block the growth of new blood vessels. | Binds to the IL-12 receptor found on activated T cells Upon binding, IL-12R-β2 provides binding sites for Tyk2 and Jak2, activating STAT4 | Pleiotropic Cytokine |
| Interleukin-15 | IL-15 | NCI | 745101 | Chen | Cytokine that regulates T and natural killer cell activation and proliferation. Shares many biological activities with interleukin 2 | Activates JAK kinases, and phosphorylation/activation of transcription activators STAT3, STAT5 and STAT6. | Cytokine |
| Ipatasertib1 | GDC-0068 | Genentech | 781451 | Pelosof | an ATP-competitive AKT inhibitor, blocks the phosphoinositide 3-kinase (PI3K)/AKT pathway | all three isoforms of AKT | Small Molecule |
| Larotrectinib | Bayer | 788607 | Pelosof | Highly-selective, tropomyosin receptor kinase (TRK) inhibitor | NTRK-1, NTRK-2, NTRK-3 gene fusions; TrkA/B/C fusion proteins | Small Molecule | |
| Lutetium | Lu177 Dotatate | Novartis | 815530 | Pelosof | Radiopharmaceutical that binds to somatostatin receptor, is internalized and accumulates in lysosomes. | Somatostatin receptor | Radiopharmaceutical |
| M1774 3 | VXc 400 or VRT 1363004 | EMD Serono (Merck KGaA) | 831851 | Gore | Selectively inhibits ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase | ATR | Small Molecule |
| M3814 | MSC2490484A | EMD Serono (Merck KGaA) | 802447 | Gore | DNA-PK inhibition, delays DNA repair of the DSB pathway in solid tumors and hematologic malignancies | DNA-dependent protein kinase (DNA-PK) | Small Molecule |
| METxMET | REGN5093 | Regeneron | 849708 | Pickett | Binds to two distinct epitopes of MET, thus blocking HGF binding and induces internalization and degradation of MET | MET (receptor tyrosine kinase) | Bispecific Antibody |
| Mezigdomide | Bristol Myers Squibb Company | Pelosof | Cereblon E3 ligase modulator (CELMoD), IKAROS family zinc finger 1 and 3 inhibitor, protein degrader | cereblon (CRBN)-E3 ligase, IKAROS family zinc finger 1&3 | Small Molecule | ||
| Mirdametinib | SpringWorks Therapeutics, Inc. | 755770 | Gore | Inhibits MAPK signaling pathway | MEK1 and MEK2 | Small Molecule | |
| Mosunetuzumab | Genentech | 833090 | Ko | Simultaneously targets CD20 on B-cells and CD3 on T-cells by redirecting endogenous T-cells to engage and eliminate tumor-specific CD20-expressing B-cells. | CD20 on B-cells and CD3 on T-cells | Full length IgG1 antibody | |
| Nemvaleukin Alfa | Alkermes, Inc. | 836408 | Chen | Binds to the IL-2R complex to preferentially activate memory cytotoxic CD8+T cells and natural killer (NK) cells without expanding CD4+ Tregs. | IL-2R complex | Engineered IL-2 variant | |
| Osimertinib | AZD9291 | AstraZeneca | 781254 | Pelosof | 3rd generation epidermal growth factor receptor mutation (mEGFR) inhibitor | mEGFR and the dominant acquired T790M resistance mutation | Small Molecule |
| Pembrolizumab | MK-3475 | Merck | 776864 | Ko | Humanized IgG4 mAb against programmed death 1 receptor (PD-1) | PD-1 | Antibody |
| Pidnarulex | CX-5461 | Senhwa Biosciences, Inc. | 845292 | Gore | G-Quadruplex-stabilizer (Quinolone Derivative) | it causes replication fork stalling and promotes DNA damage resulting in cell death homologous recombination deficiency (HRD) tumors. | Small Molecule |
| Radium223 | Radium223 | Bayer | 793433 | Pelosof | alpha particle-emitting radionuclides | Radiopharmaceutical | |
| Relatlimab 4 | BMS-986016 | Bristol-Myers Squibb | 783201 | Ko | inhibitor of the LAG-3 checkpoint receptor | LAG-3 | Monoclonal Antibody |
| Ribociclib 2 | KISQALI® | Novartis | 794613 | Pelosof | Cyclin Dependent Kinase 4 and Cyclin Dependent 6 (CDK4/6) Inhibitor | Kinase inhibitor | Small Molecule |
| Sacituzumab Govitecan | IMMU-132; TRODELVY® | Gilead Sciences, Inc. | 820016 | Pelosof | Trop-2 receptor targeted antibody-drug conjugate - inhibits topoisomerase I which leads to DNA damage leads to apoptosis of the target cells | Trop-2 receptor | Monoclonal Antibody |
| Sapanisertib | FTH-003 | Faeth therapeutics, Inc. | 768435 | Gore | Inhibits Rapamycin complex1/2 (TORC1/TORC2) kinase | TORC1/TORC2 | Small Molecule |
| Savolitinib | AZD6094 | AstraZeneca | 785348 | Pelosof | specific, small molecule inhibitor of the MET receptor kinase | cMet | Small Molecule |
| Selumetinib 1 | AZD6244 | AstraZeneca | 748727 | Pelosof | MAPK/ERK Kinase (MEK) inhibition | MEK enzyme | Small Molecule |
| Sotorasib | AMG510 | Amgen | 825510 | Pelosof | Inhibits G12C-mutated KRAS | mutated KRAS protein | Small Molecule |
| Talazoparib | BMN 673 (MDV 38000) | Pfizer | 771561 | Gore | Polyadenosine 5’diphosphoribose[poly (ADP ribose)] Polymerase (PARP) inhibitor, PARylation inhibitor and PARP trapper, Class II, strong trapper. Binding prevents PARP-mediated DNA repair of single strand DNA breaks via base-excision repair | PARP 1 and 2 inhibitor | Small Molecule |
| Tazemetostat 5 | Epizyme/Ipsen | 791066 | Pelosof | Inhibits Enhancer of zeste homolog 2 (EZH2) | EZH2 | Small Molecule | |
| Teclistamab | Janssen Research and Development, LLC | 840815 | Ko | Bispecific antibody that targets the CD3 receptor expressed on the surface of T cells and BCMA expressed on the surface of malignant multiple myeloma B lineage cells and leads to cell death of the BCMA+ cells | BCMA+ malignant B cells | Bispecific antibody | |
| Tin-117m-DTPA | Serene | Pelosof | Radiopharmaceutical that selectively accumulates in bone metastases | Radiopharmaceutical | |||
| Trametinib 1 | GSK112021 | Novartis | 763093 | Chen | Potent and highly selective inhibitor of MEK1/2 activation and kinase activity | MEK enzyme | Small Molecule |
| Trastuzumab deruxtecan | DS-8201a | Daiichi Sankyo | 807708 | Pickett | HER2-targeted antibody-drug conjugate - inhibits topoisomerase I which leads to apoptosis of the target cells | Human Epidermal Growth Factor Receptor 2 (HER2) | Monoclonal Antibody-drug conjugate |
| Triapine | Nanopharmaceutics, Inc. | 663249 | Gore | Ribonucleotide reductase (RR) inhibitor inhibits the metal binding subunit (M2) of RR, which is essential for DNA synthesis and repair. | DNA Synthesis(RR M2 subunit - Enzyme) | Small Molecule | |
| Venetoclax | ABT-199 | Abbvie/Genentech | 766270 | Gore | Bcl-2-selective inhibitor that disrupts Bcl-2 signaling in cells and rapidly induces multiple hallmarks of apoptotic cell death in Bcl-2-dependent tumor cells | Bcl-2 and with lower affinity to Bcl-XL and Bcl-w | Small Molecule |
| ZEN-3694 | ZEN003694 | Zenith Epigenetics Ltd. | 824453 | Pelosof | epigenetically regulates gene expression through BET inhibition, targeting BET proteins leads to inhibition of tumor growth in multiple cancer types, through cell cycle arrest and induction of senescence and apoptosis. | Bromodomain and Extra-Terminal motif (BET) inhibitor | Small Molecule |
| Z-endoxifen HCl | NCI | 750393 | Chen | Endoxifen, a cytochrome P450 mediated tamoxifen metabolite, is an anti-estrogen | Targets estrogen receptor-alpha | Small Molecule |
- Non-clinical requests only
- Only available for clinical studies
- Discuss with the drug monitor before preparing/submitting an LOI
- Nivolumab and Ipilimumab are only available for use in combination with relatlimab. Discussion with the drug monitor prior to submitting an LOI is recommended.
- In combination with botensilimab only
Non-Clinical Research
Investigators may request CTEP agents for non-clinical research using the appropriate request form below.
CTEP will grant these requests after receiving the industry supplier’s approval for the proposed research.
Non-Clinical Research Forms
- For AstraZeneca agents: AZ Non-Clinical Request Form
- For all other agents: General Non-Clinical Request Form